These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23856251)

  • 1. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.
    Pickup MW; Laklai H; Acerbi I; Owens P; Gorska AE; Chytil A; Aakre M; Weaver VM; Moses HL
    Cancer Res; 2013 Sep; 73(17):5336-46. PubMed ID: 23856251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
    Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
    Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Cancer Res; 2007 May; 67(10):4869-77. PubMed ID: 17495323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
    Siegel PM; Shu W; Cardiff RD; Muller WJ; Massagué J
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8430-5. PubMed ID: 12808151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.
    Shaw AK; Pickup MW; Chytil A; Aakre M; Owens P; Moses HL; Novitskiy SV
    PLoS One; 2015; 10(1):e0117908. PubMed ID: 25629162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells.
    Taylor MA; Amin JD; Kirschmann DA; Schiemann WP
    Neoplasia; 2011 May; 13(5):406-18. PubMed ID: 21532881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.
    Williams TM; Medina F; Badano I; Hazan RB; Hutchinson J; Muller WJ; Chopra NG; Scherer PE; Pestell RG; Lisanti MP
    J Biol Chem; 2004 Dec; 279(49):51630-46. PubMed ID: 15355971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
    Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
    Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
    Novitskiy SV; Forrester E; Pickup MW; Gorska AE; Chytil A; Aakre M; Polosukhina D; Owens P; Yusupova DR; Zhao Z; Ye F; Shyr Y; Moses HL
    Breast Cancer Res; 2014 Oct; 16(5):425. PubMed ID: 25280532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
    Vasiljeva O; Papazoglou A; Krüger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T
    Cancer Res; 2006 May; 66(10):5242-50. PubMed ID: 16707449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.
    Vasiukov G; Novitskaya T; Zijlstra A; Owens P; Ye F; Zhao Z; Moses HL; Blackwell T; Feoktistov I; Novitskiy SV
    Cancer Res; 2020 Jun; 80(12):2628-2638. PubMed ID: 32312837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer.
    Guillory B; Sakwe AM; Saria M; Thompson P; Adhiambo C; Koumangoye R; Ballard B; Binhazim A; Cone C; Jahanen-Dechent W; Ochieng J
    Am J Pathol; 2010 Nov; 177(5):2635-44. PubMed ID: 20847285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
    Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
    Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors.
    Grum-Schwensen B; Klingelhöfer J; Grigorian M; Almholt K; Nielsen BS; Lukanidin E; Ambartsumian N
    Cancer Res; 2010 Feb; 70(3):936-47. PubMed ID: 20103644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model.
    Roselli S; Kahl RG; Copeland BT; Naylor MJ; Weidenhofer J; Muller WJ; Ashman LK
    BMC Cancer; 2014 Jul; 14():509. PubMed ID: 25012362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.
    Novitskiy SV; Pickup MW; Gorska AE; Owens P; Chytil A; Aakre M; Wu H; Shyr Y; Moses HL
    Cancer Discov; 2011 Oct; 1(5):430-41. PubMed ID: 22408746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.